Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a type of cancer called peripheral T-cell lymphoma (PTCL), confirmed by a tissue biopsy, that has come back or stopped responding to treatment — but not the subtypes known as cutaneous T-cell lymphoma (CTCL) or T-cell prolymphocytic leukemia (TPLL).
• People whose cancer has continued to grow or returned after at least two previous treatments.
• People who are reasonably well and able to carry out daily activities, as measured by a standard medical scale (ECOG score of 0, 1, or 2).
• People whose liver is functioning well enough, based on specific blood test results falling within acceptable ranges.
• People whose kidneys are functioning well enough, based on a measure of how well the kidneys filter waste from the blood.
• People whose blood cell counts meet minimum levels at the time of screening — including white blood cells, platelets, and red blood cells — with some flexibility if the cancer has spread to the bone marrow.

Who may not be able to join:

• People who are considered suitable candidates for a stem cell transplant.
• People whose cancer is the CTCL or TPLL subtype.
• People who have cancer that has spread to, or is suspected to have spread to, the brain or spinal cord.
• People who have previously been treated with venetoclax or a type of drug called a PI3K inhibitor.
• People who are currently being treated for another active cancer (other than a type of blood cancer called NHL), with the exception of certain hormone-based treatments for prostate cancer that are stable.
• People who have received cancer treatments such as chemotherapy, radiation, or immunotherapy within the two weeks before the trial starts, with some specific exceptions (confirm with trial site).
• People who have had a stem cell transplant using donor cells within the past six months, or who still have active graft-versus-host disease requiring medication.
• People who have had a donor stem cell transplant more than six months ago but are still on immune-suppressing medication, or who are not considered medically stable.
• People with an active infection currently requiring antibiotics or other treatments.
• People who test positive for HIV, hepatitis C, or hepatitis B, or who show signs of having had a prior hepatitis B or C infection (with some specific exceptions — confirm with trial site).
• People with other serious, uncontrolled medical conditions, including active viral, bacterial, or fungal infections, or chronic hepatitis B or C requiring treatment (with some exceptions — confirm with trial site).
• People with uncontrolled autoimmune conditions causing destruction of red blood cells or platelets.
• People who have had a stroke or bleeding inside the brain.
• People with a serious bleeding disorder (such as hemophilia A or B, or von Willebrand disease), a history of spontaneous bleeding serious enough to need a blood transfusion, or a life-threatening bleed within three months before the trial starts.
• People with currently active gut conditions such as colitis, inflammatory bowel disease, or diarrhoea that requires treatment.
• People with serious, currently active heart conditions, such as an uncontrolled irregular heartbeat, severe heart failure, or a heart attack, unstable chest pain, or acute coronary event within the past six months.
• People with heart failure requiring treatment, a reduced heart pumping function (ejection fraction at or below 50%), or stable long-term chest pain (angina).
• People using a blood-thinning medication called Coumadin (warfarin).
• People who are pregnant or breastfeeding.
• People who are unable to swallow capsules, or who have conditions affecting how the gut absorbs medication, including removal of part of the stomach or small bowel, bowel obstruction, or chronic diarrhoea.
• People taking medications or eating foods that strongly affect how the body processes a specific liver enzyme called CYP3A (confirm with trial site for the specific list).
• People who, within the seven days before starting the trial, have used high-dose steroids for cancer treatment, or taken moderate or strong CYP3A-affecting medications.
• People who have eaten grapefruit, grapefruit products, Seville oranges (including marmalade made with Seville oranges), or star fruit within the seven days before starting the trial.

Important: Always verify eligibility with the trial site directly before applying.